Scientific Reports (Jun 2021)

High prevalence of symptoms among Brazilian subjects with antibodies against SARS-CoV-2

  • Ana M. B. Menezes,
  • Cesar G. Victora,
  • Fernando P. Hartwig,
  • Mariângela F. Silveira,
  • Bernardo L. Horta,
  • Aluísio J. D. Barros,
  • Marilia A. Mesenburg,
  • Fernando C. Wehrmeister,
  • Lúcia C. Pellanda,
  • Odir A. Dellagostin,
  • Cláudio J. Struchiner,
  • Marcelo N. Burattini,
  • Fernando C. Barros,
  • Pedro C. Hallal

DOI
https://doi.org/10.1038/s41598-021-92775-y
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Since the beginning of the pandemic of COVID-19, there has been a widespread assumption that most infected persons are asymptomatic. Using data from the recent wave of the EPICOVID19 study, a nationwide household-based survey including 133 cities from all states of Brazil, we estimated the proportion of people with and without antibodies for SARS-CoV-2 who were asymptomatic, which symptoms were most frequently reported, number of symptoms and the association with socio-demographic characteristics. We tested 33,205 subjects using a rapid antibody test previously validated. Information was collected before participants received the test result. Out of 849 (2.7%) participants positive for SARS-CoV-2 antibodies, only 12.1% (95% CI 10.1–14.5) reported no symptoms, compared to 42.2% (95% CI 41.7–42.8) among those negative. The largest difference between the two groups was observed for changes in smell/taste (56.5% versus 9.1%, a 6.2-fold difference). Changes in smell/taste, fever and body aches were most likely to predict positive tests as suggested by recursive partitioning tree analysis. Among individuals without any of these three symptoms, only 0.8% tested positive, compared to 18.3% of those with both fever and changes in smell or taste. Most subjects with antibodies against SARS-CoV-2 are symptomatic, even though most present only mild symptoms.